DENVER, Nov. 15 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disease, today announced that J. William Freytag, President and
Chief Executive Officer, will present a corporate overview at Credit Suisse
First Boston's Healthcare Conference.
The presentation will take place at 1:00 p.m. (Eastern) on Friday, November
19, 2004. There will be a live webcast of the presentation, which will be
accessible through a link posted on the investor relations section of the
Myogen website at http://investor.myogen.com/. The webcast will be available
for replay on Myogen's website through December 3, 2004.
Myogen currently markets one product in Europe for the treatment of acute
decompensated heart failure and has three product candidates in late-stage
clinical development: enoximone capsules for the treatment of chronic heart
failure, ambrisentan for the treatment of pulmonary arterial hypertension and
darusentan for the treatment of resistant hypertension. The Company, in
collaboration with Novartis, also conducts a target and drug discovery
research program focused on the development of disease-modifying drugs for the
treatment of chronic heart failure and related cardiovascular disorders.
Please visit our website at http://www.myogen.com.
Safe Harbor Statement
This press release and the anticipated presentation contain
forward-looking statements that involve significant risks and uncertainties,
including those discussed in this release, those to be discussed in the
presentation and others that can be found in the "Risk Factors" section of
Myogen's Form 10-K for the year ended December 31, 2003 and in Myogen's
periodic reports on Form 10-Q and Form 8-K. Myogen does not undertake any
obligation to update any forward-looking statements contained in this document
or the anticipated presentation as a result of new information, future events
or otherwise. The Company cautions investors not to place undue reliance on
the forward-looking statements contained in this press release or the
presentation. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected.
SOURCE Myogen, Inc.
 back to top
Related links:
http://investor.myogen.com
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
